Spyre Therapeutics amends 2016 Employee Stock Purchase Plan effective January 1, 2026

Spyre Therapeutics restated its ESPP to reserve 1,056,096 shares for eligible employees and participating corporations. The plan amendment enhances employee equity participation and includes provisions for both Section 423 and Non-Section 423 components for international operations.